Arnon K.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 3 Study of BGB-11417 plus Zanubrutinib versus Venetoclax plus Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
- Phase II Study of Pirtobrutinib with Epcoritamab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma. AETHER study (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL)
Data & Insights
Has run more than one trial at 64 of 184 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on developing innovative therapeutic approaches for these conditions.
- Previously untreated CLL without genetic mutations
- Relapsed/refractory CLL management
- Richter's Syndrome treatment
Their research extends to both treatment-naïve patients and those with advanced disease states.
Combination Therapies
The investigator explores novel therapeutic combinations incorporating targeted therapies and immunotherapy agents for blood cancers.
- BTK inhibitor-based combinations
- Venetoclax-based regimens
- Monoclonal antibody therapies
Their work focuses on optimizing treatment outcomes through strategic drug combinations.
Treatment Innovation
The investigator evaluates novel therapeutic approaches against traditional chemoimmunotherapy regimens in blood cancers.
- First-line treatment strategies
- Alternative therapy development
- Treatment resistance solutions
Their research aims to establish more effective and targeted treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.